


Heart failure drugs beneficial even in presence of kidney disease

25 May 2015, by Katarina Sternudd



This image shows a cross section of a kidney. Credit: Holly Fischer/Wikipedia

A novel study from Karolinska Institutet suggests that RAS-antagonists, common drugs for patients with heart failure, may benefit also patients who have concomitant kidney disease, a group previously not studied.

These drugs have proven effect in heart failure, but patients with kidney disease were excluded from clinical trials due to fear of kidney complications. While [kidney complications](#) are still a potential concern, this new study, which is presented at the annual congress of the European Society of Cardiology Heart Failure Association, and

published concurrently in the *European Heart Journal*, suggests that the net effect may be beneficial.

In the current study, a Swedish team comprising researchers at Karolinska Institutet, Linköping University, Södersjukhuset, and Karolinska University Hospital analysed data from 24,000 patients from the nationwide Swedish Heart Failure Registry (SwedeHF). Patients with heart failure and [chronic kidney disease](#) who were treated with RAS-antagonists (ACE-inhibitors or angiotensin receptor blockers) had better survival than un-treated patients.

Reduction in mortality

The difference persisted after adjustment for a large number of other factors, such as patient age and measures of general health, and the final decrease in mortality was 24 percent. The reduction in mortality was similar to that in patients without kidney disease which was in turn similar to that in randomized trials.

"This study was large and rigorous but cannot prove that RAS-antagonists are beneficial", says Dr Lars Lund at the Department of Medicine, Solna, who led the study. "It provides a rationale for performing large-scale randomized trials with this inexpensive category of drugs for the common combination of [heart failure](#) and [kidney disease](#). Indeed, Swedish health care and national population registries provide an ideal setting for a novel concept, so called registry-randomized trials."

More information: Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency – a prospective propensity score-matched cohort study, Lars H Lund, Lina Benson, Ulf Dahlström, Magnus Edner, *European Heart Journal*, 23 May 2015.

Provided by Karolinska Institutet

APA citation: Heart failure drugs beneficial even in presence of kidney disease (2015, May 25) retrieved 11 November 2022 from <https://medicalxpress.com/news/2015-05-heart-failure-drugs-beneficial-presence.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.